XTuit Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From XTuit Pharmaceuticals Inc.
Generic Blow Looms For Lundbeck
With a new CEO taking the reins in September and a candidate entering the clinic for Parkinson’s disease, Lundbeck has opportunities for refreshment, both in the pipeline and the boardroom. But with generic competition battering down the company’s financial outlook, it may not be enough to bring the market along for the ride.
Appointments: New CEOs For Lundbeck, Voyager & Neos, CSOs For iTeos & Tilos
Deborah Dunsire’s appointment to lead Lundbeck tops this week’s list of new hires; Astellas, Orchard Therapeutics, Voyager Therapeutics, iTeos Therapeutics, Cevec Pharmaceuticals, Sangamo Therapeutics, Cedilla Therapeutics, Tilos Therepautics and Neos Therapeutics have also appointed new executives and directors.
Scrip Asks… What Are The Biggest Barriers To Women In Leadership Roles?
Scrip talked to five female CEOs about the barriers in biopharma that prevent more women from reaching the top leadership ranks and their thoughts on what industry can do to improve gender diversity.
Biotech Investment Outlook Remains Strong Despite Jitters
Despite the recent volatility in the stock market, experts and industry insiders at the BIO CEO & Investor conference in New York said biotech remains a leading area to invest, predicting continued VC investment and more M&A ahead.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.